In vitro and in vivo release of naltrexone from biodegradable depot systems

Drug Development and Industrial Pharmacy

Volumn 32, Issue 1, 2006, Pages 85-94

  Liu, Yandi ^a,b   Sunderland, V Bruce ^a   O'Neil, A George ^b  

^a CURTIN UNIVERSITY   (Australia)

^b Go Medical Industries Pty Ltd   (Australia)

Author keywords

Biodegradable system; Histopathology; HPLC Poly(D,L lactide); Microspheres; Naltrexone; Release in vitro; Release in vivo; Tablet

Indexed keywords

MICROSPHERE; NALTREXONE; POLYLACTIDE; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IMPLANT; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KINETICS; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE; TABLET; TIME SERIES ANALYSIS;

ANIMALS; BIODEGRADATION, ENVIRONMENTAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; LACTIC ACID; MICROSPHERES; NALTREXONE; PARTICLE SIZE; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 32344437282     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500388466     Document Type: Article

References (42)

1. Anderson, J. M., & Wise, D. L. (1975). Lactic/Glycolic acid polymers as narcotic antagonist delivery systems. Life Sci, 17(10), 1877-1886.
2. Bell, J. R., Young, M. R., Masterman, S. C., Morris, A., Mattick, R. P., & Bammer, G. (1999). A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med. J. Aust., 71, 26-30.
3. Benichou, A., Aserin, A., & Garti, N. (2004). Double emulsions stabilized with hybrids of natural polymers for entrapment and slow release of active matters. Adv. Colloid Interface Sci., 108-109, 29-41.
4. Brewer, C. (2001). Naltrexone implants for opiate addiction: new life for a middle-aged drug. Pharm. J., 267, 260.
5. Brewer, C., & Gastfriend, D. R. (1998). Rapid opiate detoxification. JAMA, 279(23), 1872.
6. Chiang, C. N., Hollister, L. E., Kishimoto, A., & Barnett, G. (1984). Kinetics of a naltrexone sustained-release preparation. Clin. Pharmcol. Ther., 36(5), 704-708.
7. Comer, S. D., Collins, E. D., Kleber, H. D., Nuwayer, E. S., Kerrigan, J. H., & Fischman, M. W. (2002). Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacol.,, 159, 351-360.
8. Determan, A. S., Trewyn, B. G., Lin, V. S. Y., Nilsen-Hamilton, M., & Narasimhan, B. (2004). Encapsulation, stabilization, and release of BSA-FITC from polyanhydride microspheres. J. Control. Release., 100, 97-109.
9. Emmerson, P. J., Liu, M. R., Woods, J. H., & Medzihradsky, F. (1994). Binding affinity and selectivity of opioids at mu, delta, and kappa receptors in monkey brain membrane. J. Pharmacol. Exp. Ther., 271, 1630-1637.
10. Gonzalez, J. P., & Brogden, R. N. (1988). Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 35, 192-213.
11. Higuchi, T. (1963). Mechanisms of sustained action mediation. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci., 52, 1145-1149.
12. Higuchi, T. (1961). Rate of release of medicaments from ointment bases contaning drugs in suspensions. J. Pharm. Sci., 50, 874-875.
13. Hulse, G. K., & Basso, M. R. (2000). The association between naltrexone compliance and daily supervision. Drug Alcohol Rev, 19(1), 41-48.
14. Hulse, G. K., Arnold-Reed, D. E., O'Neil, G., & Robert, C. H. (2004). Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addict. Biol., 9, 67-72.
15. Hulse, G. K., O'Neil, G., Hatton, M., & Paech, M. J. (2003). A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in "high-risk" adolescent heroin users. Addict. Biol., 8, 337-342.
16. Iwata, M., & McGinity, J. W. (1993). Dissolution, stability, and morphological properties of conventional and multiphase poly(D, L-lacticco-glycolic acid) microspheres contaning water-soluble compounds. Pharmacol. Res., 10, 1219-1227.
17. Johnson, R., Jaffe, J. H., & Fudala, P. J. (1992). A controlled trial of buprenorphine treatment for opioid dependence. JAMA, 267, 2750-2755.
18. Lai, C. K., Lee, T., Au, K. M., & Chan, A. Y. W. (1997). Uniform solid-phase extraction procedure for toxicological drug screening in serum and urine by HPLC with photodiode-array detection. Clin. Chem., 43(2), 312-325.
19. Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science, 278, 45-47.
20. Maa, Y. F., & Heller, J. (1990). Controlled release of naltrexone pamoate from linear poly(ortho esters). J. Control. Release., 14, 21-28.
21. McLellan, A. T. (2002). Have we evaluated addiction treatment correctly? Implication from a chronic care perspective. Addict, 97, 249-252.
22. Millery, M., Kleinman, B. P., Polissar, N. L., Millman, R. B., & Scimeca, M. (2002). Detoxification as a gateway to long-term treatment: assessing two interventions. J. Subst. Abuse Treat., 23, 183-190.
23. Murakami, H., Kobayashi, M., Takeuchi, H., & Kawashima, Y. (2000). Utilization of poly(d, 1-lactide-co-glycolide) nanoparticles for preparation of mini-depot tablets by direct compression. J. Control. Release., 67, 29-36.
24. Negishi, N., Bennett, D. B., Cho, C. S., Jeong, S. Y., Van Heeswijk, W. A. R., Feijen, J., & Kim, S. W. (1987). Coupling of naltrexone to biodegradable poly (α-amino acids). Pharm. Res., 4, 305-310.
25. Ogawa, Y., Yamamoto, M., Takada, S., Okada, H., & Shimamoto, T. (1988). A new technique to efficiently entrap leuprolide acetate into microspheres of polylactic acid or copoly(lactic/glycolic) acid. Chem. Pharm. Bull., 36(3), 1095-1103.
26. Pays, K., Giermanska-Kahn, J., Pouligny, B., Bibette, J., & Leal-Calderon, F. (2002). Double emulsions: how does release occur? J. Control. Release., 79, 193-205.
27. Pekarek, K. J., Dyrud, M. J., Ferrer, K., Jong, Y. S., & Mathiowitz, E. (1996). In vitro and in vivo degradation of double-walled polymer microspheres. J. Control. Release., 40, 169-178.
28. San, L., Pomarol, G., Peri, J. M., Olle, J. M., & Cami, J. (1991). Follow-up after six-month maintenance period on naltrexone verus placebo in heroin addicts. Br. J. Addict., 86, 983-990.
29. Shively, M. L., Coonts, B. A., Renner, W. D., Southard, J. L., & Bennett, A. T. (1995). Physico-chemical characterization of a polymeric injectable implant delivery system. J. Control. Release., 33, 237-243.
30. Siepmann, J., Faisant, N., Akiki, J., Richard, J., & Benoit, J. P. (2004). Effect of the size of biodegradable microparticles on drug release: experiment and theory. J. Control. Release., 96, 123-134.
31. Siepmann, J., Faisant, N., & Benoit, J. P. (2002). A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carle simulation. Pharm. Res., 19, 1885-1893.
32. Stine, S. M., Meandzjia, B., & Kosten, T. R. (1998). In Principles of Addiction Medicine, (2nd Ed.), Graham, A. W., Schults, T. K., Eds.; American Society of Addiction Medicine: Chevy Chase, MD, 545-555.
33. Therin, M., Christel, P, Li, S., Garreau, H., & Vert, M. (1992). In vivo degradation of massive poly(alpha-hydroxy acids): validation of in vitro findings. Biomaterials., 13, 594-600.
34. Uchida, T., Yoshida, K., Nakada, Y., Nagareya, N., Konishi, Y., Nakai, K., Nishikata, M., & Matsuyama, K. (1997). Preparation and characterization of polylactic acid microspheres containing water-soluble anesthetics with small molecular weight. Chem. Pharm. Bull., 45(3), 513-517.
35. Valiveti, S., Paudel, K. S., Hammell, D. C., Hamad, M. O., Chen, J., Crooks, P. A., & Stinchcomb, A. L. (2005). In vitro/in vivo correlation of transdermal NTX prodrugs in hairless guinea pigs. Pharm. Res., 22(6), 981-9.
36. Vereby, K., Volavka, J., Mule, S. J., & Resenicks, R. B. (1976). Naltrexone: Disposition, metabolism and effects after acute and chronic dosing. Clin. Pharmacol. Ther., 20(3), 315-328.
37. Wall, M. E., Braine, R. D., & Perez-Reyes, M. (1981). Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab. Dispos., 9, 370-375.
38. Wang, Y. M., Sato, H., & Horikoshi, I. (1997). In vitro and in vivo evaluation of taxol release from poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres. J. Control. Release., 49, 157-166.
39. Wise, D. L. (1984). In Biopolymeric Controlled Release Systems, Wise, D. L., Ed.; Florida, CRC: Boca Raton, vol. 1, 115-181.
40. Woody, G. E., McLellan, A. T., Luborsky, L., & O'Brain, C. P. (1993). The effects of psychosocial services in substance abuse treatment. JAMA, 269, 1953-1959.
41. Yamaguchi, K., & Anderson, J. M. (1993). Biocompatibility studies of naltrexone sustained release formulations. J. Control. Release., 19, 299-314.
42. Yolles, S., Leafe, T. D., Woodland, J. H. R., & Meyer, F. J. (1975). Long acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composites. J. Pharm. Sci., 64(2), 348-349.